A phase I trial of andrographolide in HIV positive patients and normal volunteers

Carlo Calabrese, Sheryl H. Berman, John G. Babish, Ma Xinfang, Lynne Shinto, Melissa Dorr, Kameron Wells, Cynthia A. Wenner, Leanna J. Standish

Research output: Contribution to journalArticle

255 Citations (Scopus)

Abstract

A phase I dose-escalating clinical trial of andrographolide from Andrographis paniculata was conducted in 13 HIV positive patients and five HIV uninfected, healthy volunteers. The objectives were primarily to assess safety and tolerability and secondarily to assess effects on plasma virion HIV-1 RNA levels and CD4+ lymphocyte levels. No subjects used antiretroviral medications during the trial. Those with liver or renal abnormalities were excluded. The planned regimen was 5 mg/kg bodyweight for 3 weeks, escalating to 10 mg/kg bodyweight for 3 weeks, and to 20 mg/kg bodyweight for a final 3 weeks. The trial was interupted at 6 weeks due to adverse events including an anaphylactic reaction in one patient. All adverse events had resolved by the end of observation. A significant rise in the mean CD4+ lymphocyte level of HIV subjects occurred after administration of 10 mg/kg andrographolide (from a baseline of 405 cells/mm3 to 501 cells/mm3; p = 0.002). There were no statistically significant changes in mean plasma HIV-1 RNA levels throughout the trial. Andrographolide may inhibit HIV-induced cell cycle dysregulation, leading to a rise in CD4+ lymphocyte levels in HIV-1 infected individuals. Copyright (C) 2000 John Wiley and Sons, Ltd.

Original languageEnglish (US)
Pages (from-to)333-338
Number of pages6
JournalPhytotherapy Research
Volume14
Issue number5
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Lymphocytes
Healthy Volunteers
HIV
HIV-1
RNA
Plasmas
Andrographis
Liver
Anaphylaxis
Cells
Virion
Cell Cycle
Observation
Clinical Trials
Kidney
Safety
andrographolide

Keywords

  • AIDS
  • Andrographis paniculata
  • Andrographolide
  • CD4 lymphocytes
  • HIV-1

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

A phase I trial of andrographolide in HIV positive patients and normal volunteers. / Calabrese, Carlo; Berman, Sheryl H.; Babish, John G.; Xinfang, Ma; Shinto, Lynne; Dorr, Melissa; Wells, Kameron; Wenner, Cynthia A.; Standish, Leanna J.

In: Phytotherapy Research, Vol. 14, No. 5, 2000, p. 333-338.

Research output: Contribution to journalArticle

Calabrese, C, Berman, SH, Babish, JG, Xinfang, M, Shinto, L, Dorr, M, Wells, K, Wenner, CA & Standish, LJ 2000, 'A phase I trial of andrographolide in HIV positive patients and normal volunteers', Phytotherapy Research, vol. 14, no. 5, pp. 333-338. https://doi.org/10.1002/1099-1573(200008)14:5<333::AID-PTR584>3.0.CO;2-D
Calabrese, Carlo ; Berman, Sheryl H. ; Babish, John G. ; Xinfang, Ma ; Shinto, Lynne ; Dorr, Melissa ; Wells, Kameron ; Wenner, Cynthia A. ; Standish, Leanna J. / A phase I trial of andrographolide in HIV positive patients and normal volunteers. In: Phytotherapy Research. 2000 ; Vol. 14, No. 5. pp. 333-338.
@article{67a0c4db22d8456ba63004b2b77b6abd,
title = "A phase I trial of andrographolide in HIV positive patients and normal volunteers",
abstract = "A phase I dose-escalating clinical trial of andrographolide from Andrographis paniculata was conducted in 13 HIV positive patients and five HIV uninfected, healthy volunteers. The objectives were primarily to assess safety and tolerability and secondarily to assess effects on plasma virion HIV-1 RNA levels and CD4+ lymphocyte levels. No subjects used antiretroviral medications during the trial. Those with liver or renal abnormalities were excluded. The planned regimen was 5 mg/kg bodyweight for 3 weeks, escalating to 10 mg/kg bodyweight for 3 weeks, and to 20 mg/kg bodyweight for a final 3 weeks. The trial was interupted at 6 weeks due to adverse events including an anaphylactic reaction in one patient. All adverse events had resolved by the end of observation. A significant rise in the mean CD4+ lymphocyte level of HIV subjects occurred after administration of 10 mg/kg andrographolide (from a baseline of 405 cells/mm3 to 501 cells/mm3; p = 0.002). There were no statistically significant changes in mean plasma HIV-1 RNA levels throughout the trial. Andrographolide may inhibit HIV-induced cell cycle dysregulation, leading to a rise in CD4+ lymphocyte levels in HIV-1 infected individuals. Copyright (C) 2000 John Wiley and Sons, Ltd.",
keywords = "AIDS, Andrographis paniculata, Andrographolide, CD4 lymphocytes, HIV-1",
author = "Carlo Calabrese and Berman, {Sheryl H.} and Babish, {John G.} and Ma Xinfang and Lynne Shinto and Melissa Dorr and Kameron Wells and Wenner, {Cynthia A.} and Standish, {Leanna J.}",
year = "2000",
doi = "10.1002/1099-1573(200008)14:5<333::AID-PTR584>3.0.CO;2-D",
language = "English (US)",
volume = "14",
pages = "333--338",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - A phase I trial of andrographolide in HIV positive patients and normal volunteers

AU - Calabrese, Carlo

AU - Berman, Sheryl H.

AU - Babish, John G.

AU - Xinfang, Ma

AU - Shinto, Lynne

AU - Dorr, Melissa

AU - Wells, Kameron

AU - Wenner, Cynthia A.

AU - Standish, Leanna J.

PY - 2000

Y1 - 2000

N2 - A phase I dose-escalating clinical trial of andrographolide from Andrographis paniculata was conducted in 13 HIV positive patients and five HIV uninfected, healthy volunteers. The objectives were primarily to assess safety and tolerability and secondarily to assess effects on plasma virion HIV-1 RNA levels and CD4+ lymphocyte levels. No subjects used antiretroviral medications during the trial. Those with liver or renal abnormalities were excluded. The planned regimen was 5 mg/kg bodyweight for 3 weeks, escalating to 10 mg/kg bodyweight for 3 weeks, and to 20 mg/kg bodyweight for a final 3 weeks. The trial was interupted at 6 weeks due to adverse events including an anaphylactic reaction in one patient. All adverse events had resolved by the end of observation. A significant rise in the mean CD4+ lymphocyte level of HIV subjects occurred after administration of 10 mg/kg andrographolide (from a baseline of 405 cells/mm3 to 501 cells/mm3; p = 0.002). There were no statistically significant changes in mean plasma HIV-1 RNA levels throughout the trial. Andrographolide may inhibit HIV-induced cell cycle dysregulation, leading to a rise in CD4+ lymphocyte levels in HIV-1 infected individuals. Copyright (C) 2000 John Wiley and Sons, Ltd.

AB - A phase I dose-escalating clinical trial of andrographolide from Andrographis paniculata was conducted in 13 HIV positive patients and five HIV uninfected, healthy volunteers. The objectives were primarily to assess safety and tolerability and secondarily to assess effects on plasma virion HIV-1 RNA levels and CD4+ lymphocyte levels. No subjects used antiretroviral medications during the trial. Those with liver or renal abnormalities were excluded. The planned regimen was 5 mg/kg bodyweight for 3 weeks, escalating to 10 mg/kg bodyweight for 3 weeks, and to 20 mg/kg bodyweight for a final 3 weeks. The trial was interupted at 6 weeks due to adverse events including an anaphylactic reaction in one patient. All adverse events had resolved by the end of observation. A significant rise in the mean CD4+ lymphocyte level of HIV subjects occurred after administration of 10 mg/kg andrographolide (from a baseline of 405 cells/mm3 to 501 cells/mm3; p = 0.002). There were no statistically significant changes in mean plasma HIV-1 RNA levels throughout the trial. Andrographolide may inhibit HIV-induced cell cycle dysregulation, leading to a rise in CD4+ lymphocyte levels in HIV-1 infected individuals. Copyright (C) 2000 John Wiley and Sons, Ltd.

KW - AIDS

KW - Andrographis paniculata

KW - Andrographolide

KW - CD4 lymphocytes

KW - HIV-1

UR - http://www.scopus.com/inward/record.url?scp=0033846074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033846074&partnerID=8YFLogxK

U2 - 10.1002/1099-1573(200008)14:5<333::AID-PTR584>3.0.CO;2-D

DO - 10.1002/1099-1573(200008)14:5<333::AID-PTR584>3.0.CO;2-D

M3 - Article

C2 - 10925397

AN - SCOPUS:0033846074

VL - 14

SP - 333

EP - 338

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 5

ER -